Composition for external use on skin for inflammatory diseases

• US 9,220,702 B2
• Filed: 05/11/2012
• Issued: 12/29/2015
• Est. Priority Date: 05/12/2011
• Status: Active Grant

• Current Assignee: Nissui Corp.
• Original Assignee: Nippon Suisan Kaisha Limited
• Inventors: Takeo, Jiro, Kawahara, Hiroyuki
• Primary Examiner(s): TRAN, MY CHAU T
• Application Number:
  US14/117,330
• Publication Number:
  US 20140275251A1
• Time in Patent Office: 1,327 Days
• Field of Search: 514/547, 514/549, 514/560
• US Class Current: 1/1
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 31/232 having three or more double bonds, e.g. etretinate
• CPC Class Codes: A61K 31/683 Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
• CPC Class Codes: A61K 31/685 one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• CPC Class Codes: A61K 31/7032 attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
• CPC Class Codes: A61K 47/06 Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14

Abstract

[Problem] Provision of a composition for external use on skin that is safe to use and has an anti-inflammatory and anti-allergic actions. [Solution] A composition for external use on skin in the treatment of inflammatory disease which comprises dihomo-γ-linolenic acid (DGLA) as an active ingredient. The DGLA is preferably contained as a glyceride, a phospholipid, or an alkyl ester. The composition for external use contains DGLA in an amount of 0.1-50 wt %.

Claims

1. A method of treating inflammatory disease comprising administering topically, to the skin of a patient in need thereof, an effective amount of a pharmaceutical composition consisting of dihomo-γ

-linolenic acid (DGLA) in the form of a free fatty acid, a pharmaceutical base, and optionally including absorption promoters, moisturizers, thickeners, emulsifying agents, colorants, fragrances, antioxidants, stabilizers, sterilizers, and antiseptics.

2. The method according to claim 1, wherein the composition contains 0.05 to 10 wt % of the dihomo-γ

-linolenic acid (DGLA).

3. The method according to claim 1, wherein the inflammatory disease is an inflammatory skin disease.

4. The method according to claim 3, wherein the inflammatory disease is atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, psoriasis, rheumatism, or lupus.

5. The method according to claim 1, wherein the composition is applied continuously for at least 7 consecutive days to an area affected by the inflammatory disease.

6. The method according to claim 5, wherein the composition contains 0.05 to 7 wt % of the dihomo-γ

-linolenic acid (DGLA).

7. The method according to claim 1, wherein the composition contains 0.05 to 10 wt % of the dihomo-γ

-linolenic acid (DGLA) and wherein the composition is applied continuously for at least 10 consecutive days to an area affected by the inflammatory disease.

8. The method according toclaim 1, wherein the composition contains 0.05 to 10 wt % of the dihomo-γ

-linolenic acid (DGLA) and wherein the composition is applied continuously for at least 14 consecutive days to an area affected by the inflammatory disease.

10. The method according to claim 1, wherein the pharmaceutical base is selected from the group consisting of white petrolatum, cetanol, stearayl alcohol, stearic acid, white beeswax, liquid paraffin, lauromacrogol, squalene, squalene, lanolin, isobutyl myristate, and middle-chain fatty acid triglyceride.

9. A method of suppressing itch of an inflammatory disease comprising administering topically, to the skin of a patient in need thereof, an effective amount of dihomo-γ

-linolenic acid (DGLA) in the form of a free fatty acid.

11. A method for treating inflammatory disease comprising administering topically, to the skin of a patient in need thereof, an effective amount of an ointment consisting of dihomo-γ

-linolenic acid (DGLA) in the form of a free fatty acid, an ointment base, and optionally including absorption promoters, moisturizers, thickeners, emulsifying agents, colorants, fragrances, antioxidants, stabilizers, sterilizers, and antiseptics.